ACLY and autoimmune polyendocrinopathy: In our previous study, we observed that 83% of 120 patients with APS had anti-β2GPI/HLA-DR antibodies; however, approximately 50% of patients with APS who had anti-β2GPI/HLA-DR antibodies were negative for IgG anti-cardiolipin (aCL) or IgG anti-β2-glycoprotein I antibody (aβ2GPI) [11].